Quarterly ResultMay 7, 2026, 07:13 AM
Ironwood Q1 2026 LINZESS US Net Sales +97% to $273M; Maintains FY26 Guidance
AI Summary
Ironwood Pharmaceuticals reported strong first quarter 2026 financial results, driven by a 97% year-over-year increase in LINZESS U.S. net sales to $273 million. The company achieved total revenue of $107 million, GAAP net income of $41 million, and adjusted EBITDA of $77 million, while maintaining its full-year 2026 financial guidance. Additionally, Ironwood is progressing with its apraglutide Phase 3 confirmatory trial and received priority review for a LINZESS sNDA for functional constipation in young children.
Key Highlights
- LINZESS U.S. net sales were $272.5 million in Q1 2026, a 97% increase year-over-year.
- Total revenue reached $106.5 million in Q1 2026, up from $41.1 million in Q1 2025.
- GAAP net income was $40.8 million ($0.24 diluted EPS) in Q1 2026, compared to a net loss of $37.4 million in Q1 2025.
- Adjusted EBITDA was $76.7 million in Q1 2026, a significant improvement from a loss of $4.7 million in Q1 2025.
- LINZESS U.S. prescription demand increased by 5% year-over-year in Q1 2026.
- FDA accepted sNDA for LINZESS in functional constipation (2-5 years) with priority review, PDUFA date May 24th.
- Company is on track to begin site initiations for the Phase 3 confirmatory trial of apraglutide in SBS-IF in Q2 2026.
- Full-year 2026 guidance maintained: U.S. LINZESS Net Sales $1.125-$1.175 billion, Total Revenue $450-$475 million, Adjusted EBITDA >$300 million.